DYN
NASD Dyne Therapeutics Inc$15.47 ↑ +0.03 (+0.19%) Trading Up from the previous close of $15.44
- YTD change
- -20.91%
- vs 20-day SMA
- -9.84%
- vs 200-day SMA
- -21.04%
Price ranges
Price & Performance
-2.91 (-15.86%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 67.4% away from all-time highs of $47.45
- DYN is down 21% since the beginning of the year
- DYN is up 22% over the past 12 months
- DYN is down 36% over the past 1 month
- 14% of all DYN investors are betting against DYN
DYN reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +22.1%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -5.32%
- vs 8-day SMA
- -3.05%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
